Lipum AB (publ) has published the interim report for period January to March for 2023. Below is a summary, a complete report (only in Swedish) is available on the company's website.
CEO Einar Pontén comments: “I am excited about our ongoing Phase 1 clinical trial of the drug candidate SOL-116 as everything is going according to plan.”
Financial summary January – March 2023
- Net sales: KSEK 0 (0)
- Result after financial items: KSEK -7,173 (-5,830)
- Cash and cash equivalents as of March 31: KSEK 26,765 (27,971)
Significant events during the period January – March 2023
- The ongoing clinical phase 1 study with the drug candidate SOL-116 is progressing as planned after dosing four groups of healthy subjects.
Significant events after the period
- Carl-Johan Spak was nominated as new board member of Lipum AB.
CEO Einar Pontén comments on the report in a live webcast on April 25 at 09:00, link.